Small Molecule Composition for Cardiomyocyte Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human pluripotent stem cells into cardiomyocytes have low efficiency and stability, and are costly, making them unsuitable for large-scale production and therapeutic applications.
Innovation Solution
A small molecule compound composition comprising an mTOR signaling pathway inhibitor and a Wnt pathway promoter, such as rapamycin and CHIR99021, is used to promote cardiomyocyte differentiation, achieving high efficiency and purity of cardiomyocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional co-culture methods with END-2 cells or embryonic bodies are used, then cardiomyocytes can be obtained, but differentiation efficiency is very low (less than 5%) and production cost is high
Solution Approach 1:
The invention changes the chemical parameters of the differentiation system by replacing biological factors (serum, cytokines) with small molecule compounds (CHIR99021, IWP2, purmorphamine) at precisely controlled concentrations. This parameter transformation enables efficient cardiomyocyte differentiation without requiring co-culture systems or embryonic bodies, thereby increasing productivity and reducing manufacturing complexity
Solution Approach 2:
The invention extracts and eliminates the need for complex co-culture systems (END-2 cells) and embryonic body formation steps. By identifying and removing these unnecessary components, the differentiation process is simplified to a direct small molecule-induced protocol, achieving high efficiency while reducing production costs
2Productivity
If cytokine-based differentiation methods (activin A, BMP4, Wnt3a, DKK1) are used, then differentiation efficiency can reach 30%, but the process complexity increases and stability between different cell lines remains insufficient
Solution Approach 1:
The invention substitutes the complex biological cytokine system (activin A, BMP4, Wnt3a, DKK1 requiring sequential addition and modulation) with a simplified small molecule compound system (CHIR99021, IWP2, purmorphamine). This replacement maintains high differentiation efficiency while dramatically reducing process complexity and improving stability across different cell lines
Solution Approach 2:
The invention segments the differentiation process into distinct temporal phases with specific small molecule combinations: early stage (CHIR99021 + IWP2), middle stage (CHIR99021 + purmorphamine), and late stage (CHIR99021 alone). This segmented approach simplifies the control of complex differentiation events compared to cytokine-based methods
3Reliability
If monolayer differentiation system with cytokines is used, then differentiation efficiency of 30% can be achieved, but stability and consistency between different cell lines (H7 vs H9) is unsatisfactory
Solution Approach 1:
The invention changes the chemical parameters from cytokine concentrations (ng/mL range) to small molecule concentrations (μM and nM range), which provide more precise and reproducible control. This parameter transformation achieves both high differentiation efficiency (85-99.9%) and improved stability across different cell lines including H9 and H7
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly increases cardiomyocyte differentiation rates to 85-99.9% and reduces production costs by half, producing cardiomyocytes with high maturity and normal myocardial function.
Implementation Method 1
a combination of small molecule compounds which comprises: (i) an inhibitor of mTOR signaling pathway; and (ii) a promoter of Wnt pathway
Data Source
AI summary
Disclosed is a small molecule compound composition that efficiently induces the differentiation of human pluripotent stem cells into myocardial cells. In particular, provided in the present invention is a small molecule compound composition. The small molecule compound composition comprises the following components: (i) an mTOR signaling pathway inhibitor; (ii) a Wnt pathway promoter; and (iii) optionally, a pharmaceutically acceptable carrier. The small molecule compound composition in the present invention can efficiently induce the differentiation of human pluripotent stem cells into myocardial cells. The preliminarily screened cardiomyocyte differentiation rate reaches up to 86%, and the optimized cardiomyocyte differentiation rate reaches up to 98.3%.